

# UCLA

## UCLA Previously Published Works

### Title

Phr-peptide signaling by *S. pneumoniae*

### Permalink

<https://escholarship.org/uc/item/2c43h6vm>

### Journal

Molecular Microbiology, 97(2)

### ISSN

0950-382X

### Authors

Hoover, Sharon E  
Perez, Amilcar J  
Tsui, Ho-Ching T  
[et al.](#)

### Publication Date

2015-07-01

### DOI

10.1111/mmi.13029

Peer reviewed

1  
2 **A new quorum sensing system (TprA/PhrA) for *Streptococcus pneumoniae* D39 that**  
3 **regulates a lantibiotic biosynthesis gene cluster**  
4  
5

6 Sharon E. Hoover<sup>1</sup>, Amilcar J. Perez<sup>1</sup>, Ho-Ching T. Tsui<sup>2</sup>, Dhriti Sinha<sup>2</sup>, David L. Smiley<sup>3</sup>, Richard  
7 D. DiMarchi<sup>3</sup>, Malcolm E. Winkler<sup>2</sup>, and Beth A. Lazazzera<sup>1</sup>  
8  
9

10  
11 <sup>1</sup>Department of Microbiology, Immunology and Molecular Genetics, University of California, Los  
12 Angeles, 609 Charles E. Young Dr. East, 1602 Molecular Science Building, Los Angeles,  
13 California 90095

14 <sup>2</sup>Department of Biology, Indiana University Bloomington, Jordan Hall; 1001 East Third Street;  
15 Bloomington, Indiana 47405

16 <sup>3</sup>Department of Chemistry, Indiana University Bloomington, 800 E. Kirkwood Avenue,  
17 Bloomington, Indiana 47405  
18  
19  
20  
21  
22  
23

24 Corresponding Author:  
25 Beth A. Lazazzera  
26 Department of Microbiology, Immunology, and Molecular Genetics  
27 609 Charles E. Young Dr. East  
28 1602 Molecular Science Building  
29 University of California, Los Angeles  
30 Los Angeles, CA 90095  
31  
32 (310) 794-4804 (voice)  
33 (310) 206-5231 (fax)  
34 [BethL@microbio.ucla.edu](mailto:BethL@microbio.ucla.edu)  
35  
36  
37

38 Running Title: Phr-peptide signaling by *S. pneumoniae*

39 Keywords: Quorum sensing, Phr peptides, Lantibiotics, *Pneumococcus*

40 **ABSTRACT**

41           The Phr peptides of *Bacillus* species mediate quorum sensing, but their identification  
42 and function in other species of bacteria has not been determined. We have identified a Phr  
43 peptide quorum sensing system (TprA/PhrA) that controls the expression of a lantibiotic gene  
44 cluster in the Gram-positive human pathogen, *Streptococcus pneumoniae*. Lantibiotics are  
45 highly modified peptides that are part of the bacteriocin family of antimicrobial peptides. We  
46 have characterized the basic mechanism for a Phr peptide signaling system in *S. pneumoniae*  
47 and found that it induces expression of the lantibiotic genes when pneumococcal cells are at  
48 high density in the presence of galactose, a main sugar of the human nasopharynx, a highly  
49 competitive microbial environment. Activity of the Phr peptide system is not seen when  
50 pneumococcal cells are grown with glucose, the preferred carbon source and the most  
51 prevalent sugar encountered by *S. pneumoniae* during invasive disease. Thus, the lantibiotic  
52 genes are expressed under the control of both cell density signals via the Phr peptide system  
53 and nutritional signals from the carbon source present, suggesting that quorum sensing and the  
54 lantibiotic machinery may help pneumococcal cells compete for space and resources during  
55 colonization of the nasopharynx.

## 56 INTRODUCTION

57 Quorum sensing is carried out by small secreted molecules that diffuse through  
58 the environment, eliciting responses in proximal cells when the signaling molecules  
59 reach a critical threshold concentration ([Keller & Surette, 2006](#), [Waters & Bassler,](#)  
60 [2005](#)). In Gram-positive bacteria, quorum sensing often relies on recognition of small  
61 secreted peptides that signal through two-component regulatory systems ([Rutherford &](#)  
62 [Bassler, 2012](#), [Pottathil & Lazazzera, 2003](#), [Lyon & Novick, 2004](#)). An alternative group of  
63 quorum sensing peptides are those that signal to cells by interacting with an oligopeptide  
64 transporter and then a cytoplasmic receptor protein, which is either a member of the RNPP or  
65 the Rgg family of proteins ([Rocha-Estrada et al., 2010](#), [Dunny, 2007](#), [Jimenez & Federle, 2014](#),  
66 [Fleuchot et al., 2011](#), [Pottathil & Lazazzera, 2003](#)). The Phr family of signaling peptides of Bacilli  
67 belongs to the latter group, and these peptides regulate a number of important processes such  
68 as sporulation, development of genetic competence, virulence gene expression, biofilm  
69 formation, and excision and transfer of mobile genetic elements ([Rocha-Estrada et al., 2010](#),  
70 [Slamti & Lereclus, 2002](#), [Lazazzera et al., 1997](#), [Auchtung et al., 2005](#), [Bongiorni et al., 2005](#),  
71 [Perego & Hoch, 1996](#)). However, the role that the Phr signaling peptides play outside of the  
72 Gram-positive endospore forming bacterial species has not yet been established.

73 The Phr family of quorum sensing peptide of Bacilli are secreted through the  
74 Sec-dependent export pathway and processed from a small precursor protein to a  
75 mature, 5-7 residue, polar peptide ([Mirouze et al., 2011](#), [Aceves-Diez et al., 2007](#),  
76 [Ogura et al., 2003](#), [Perego, 1997](#), [Solomon et al., 1996](#), [Bongiorni et al., 2006](#)). These  
77 peptides are encoded by genes typically found immediately adjacent to genes encoding  
78 their cytoplasmic target proteins, forming a quorum-sensing cassette ([Pottathil &](#)  
79 [Lazazzera, 2003](#), [Rocha-Estrada et al., 2010](#)). A classic example of the Phr peptides is  
80 competence and sporulation factor (CSF) of *Bacillus subtilis* ([Pottathil & Lazazzera, 2003](#)). The

81 precursor protein for CSF, PhrC, has an N-terminal signal sequence for Sec-dependent export,  
82 and the CSF pentapeptide is derived from the C-terminus of the protein through processing by  
83 extracellular proteases ([Solomon et al., 1996](#), [Lanigan-Gerdes et al., 2007](#), [Lanigan-Gerdes et](#)  
84 [al., 2008](#)). Once CSF has reached a critical concentration, it is transported into the cell by an  
85 oligopeptide permease (Opp) and interacts with at least two intracellular receptors, RapC and  
86 RapB, to inhibit their activity ([Core & Perego, 2003](#), [Lazazzera et al., 1997](#), [Perego, 1997](#)). Both  
87 RapB and RapC control the activity of response regulators involved in the regulation of  
88 sporulation and genetic competence, respectively ([Core & Perego, 2003](#), [Ishikawa et al., 2002](#),  
89 [Parashar et al., 2013](#)). A number of Phr peptide signaling cassettes have been found in the  
90 genomes of other Gram-positive endospore forming *Bacilli* and *Clostridia* species ([Perego &](#)  
91 [Brannigan, 2001](#), [Pottathil & Lazazzera, 2003](#), [Slamti & Lereclus, 2005](#), [Bongiorni et al., 2006](#),  
92 [Rocha-Estrada et al., 2010](#)). Of the non-*B. subtilis* cassettes, the best studied is the PlcR/PapR  
93 cassette of *B. cereus* and *B. thuringiensis*, in which the secreted Phr signaling peptide produced  
94 by *papR* activates the transcription factor PlcR to simulate virulence gene expression ([Slamti &](#)  
95 [Lereclus, 2002](#), [Grenha et al., 2013](#), [Gohar et al., 2008](#), [Sastalla et al., 2010](#)).

96         Several lines of evidence suggested that Phr peptides may play a role in the physiology  
97 of *Streptococcus pneumoniae* (pneumococcus), an important Gram-positive commensal  
98 bacterium that colonizes the human nasopharynx and is a serious opportunistic pathogen,  
99 causing significant health and financial burdens worldwide ([2007](#), [O'Brien et al., 2009](#), [Huang et](#)  
100 [al., 2011](#)). Pneumococcal Opp (encoded by *amiACDEF*), the homologue to the transporter  
101 necessary for import of *phr* peptides in *Bacilli*, is important for colonization and virulence in this  
102 organism ([Chen et al., 2008](#), [Hava & Camilli, 2002](#), [Molzen et al., 2011](#), [Orihuela et al., 2004](#),  
103 [Song et al., 2008](#)). How Opp influences these processes is unknown, but knockout of Opp in *S.*  
104 *pneumoniae* has highly pleiotropic effects, influencing amino acid uptake, adherence to human  
105 epithelial cells, and development of genetic competence ([Claverys et al., 2000](#), [Trombe et al.,](#)  
106 [1984](#), [Trombe et al., 1979](#), [Alloing et al., 1996](#), [Cundell et al., 1995](#)). Additionally, Opp is

107 upregulated in pneumococcal cells exposed to human lung epithelial cells ([Song et al., 2008](#)).  
108 As Opp plays such a central role in the physiology of *S. pneumoniae* and is essential for Phr  
109 peptide uptake in Bacilli, we hypothesized that Phr-type peptides could play a role in *S.*  
110 *pneumoniae* colonization or virulence.

111         Here we report the identification of genes involved in Phr-peptide signaling from *S.*  
112 *pneumoniae*. One of the Phr-peptide signaling systems, termed TprA/PhrA, is highly conserved  
113 amongst different pneumococcal serotype strains. Analysis of TprA/PhrA in *S. pneumoniae*  
114 serotype 2 strain D39 revealed that this system mediates quorum sensing and is active in media  
115 containing galactose, one of the main carbon sources encountered by pneumococcal cells  
116 during colonization of the nasopharynx. Additionally, we determined that the system controls  
117 expression of a lantibiotic biosynthesis gene cluster with the potential to produce antimicrobial  
118 peptides that may be important for competitive fitness during nasopharynx colonization.

## 119 RESULTS

### 120 *In silico* identification of a conserved *phr* peptide quorum sensing cassette in *S.*

### 121 *pneumoniae*

122 To identify Phr peptide sensing systems in different species of *Streptococcus*, we blasted  
123 sequenced Streptococcal genomes for gene encoding proteins with similarities to the PlcR/Rap  
124 regulatory proteins of Bacilli. The region neighboring these genes was then searched for  
125 adjacent small open reading frames with the features of Phr peptides, encoding 30 to 100  
126 residue peptide with an N-terminal signal sequence for export and a polar C-terminal region  
127 (see *Supplemental Information* for details). Using this method, we identified 53 potential Phr  
128 peptide-signaling cassettes in sequenced Streptococcal genomes (see Tables S1-3 for the  
129 complete list). In all of the cassettes identified, only homologues to PlcR from the *B. cereus*  
130 group were identified, and no homologues to the Rap proteins of *B. subtilis* were found. These  
131 PlcR-like proteins were also suggested previously to be putative Rgg transcription factors  
132 ([Fleuchot et al., 2011](#)). However, these proteins lacked the adjacent gene for a small  
133 hydrophobic peptide (SHP) that is typically associated with Rgg proteins. Instead, we  
134 determined that these proteins were adjacent to small genes that have the features of Phr-type  
135 peptides (an N-terminal secretion signal and C-terminal polar region). To further determine if  
136 these cassettes could be best described as orthologs of the PlcR/PapR system of Bacilli, the  
137 secondary and tertiary structure predictions for one cassette from *S. pneumoniae* were  
138 determined using Phyre<sup>2</sup> ([Kelley & Sternberg, 2009](#)). The protein structure that most closely  
139 resembled the predict structure of the protein from *S. pneumoniae* was PlcR of *B. thuringiensis*  
140 (Table S4 and Figure S1). Additionally, pairwise Blast analysis revealed that these *S.*  
141 *pneumoniae* proteins were more similar to PlcR of *B. cereus* (E-value of  $2e^{-12}$ ) than Rgg2 of  
142 *Streptococcus pyogenes* (E-value of  $3e^{-05}$ ). Thus, these gene cassettes of *S. pneumoniae*  
143 appear to be orthologs of PlcR/PapR system.

144 PlcR orthologs were found in several Streptococcal species; however, in *S. pneumoniae*  
145 strains, the orthologs were mainly encoded adjacent to a *phr* gene (Tables S1-3). Three distinct  
146 Phr peptide-signaling cassettes were found in *S. pneumoniae* strains. Each of these cassettes  
147 has a gene for a secreted Phr peptide and a gene for a transcription factor, the PlcR ortholog,  
148 which we refer to as *tpr*, for transcription factor regulated by a Phr peptide. The first cassette  
149 (TprA/PhrA; Table S1) is conserved across 60% of sequenced pneumococcal genomes. The  
150 two other peptide systems (TprB/PhrB; Table S2 and TprC/PhrC; Table S3) are present in  
151 islands of horizontally transferred genes, including pathogenicity island 1 (PI1) and region of  
152 diversity 2 (RD2) both in TIGR4 ([Blomberg et al., 2009](#), [Brown et al., 2004](#), [Obert et al., 2006](#)).



153           The *tprA/phrA* cassette of *S. pneumoniae* differs from the typical Phr-signaling cassettes.  
154   The *tprA* and *phrA* genes are oriented in opposite directions, as compared to all known Phr-  
155   signaling cassettes that have the genes oriented in the same direction ([Pottathil & Lazazzera,](#)  
156   [2003](#), [Pomerantsev et al., 2009](#)). Interestingly, this is similar to the arrangement of the some of  
157   the Rgg/SHP peptide signaling cassettes ([Chang et al., 2011](#), [Fleuchot et al., 2011](#)).  
158   Additionally, *phrA* encodes a 56-residue peptide, which is only surpassed in length by the 57-  
159   residue PhrH of *B. subtilis* and is longer than the other characterized Phr peptides of 38 to 48  
160   residues ([Slamti & Lereclus, 2002](#), [Pottathil & Lazazzera, 2003](#), [Mirouze et al., 2011](#)). These  
161   differences are indicative of the distinct evolutionary trajectory of this *S. pneumoniae* Phr-  
162   signaling cassette.

163

164   **TprA is an inhibitor of *phrA* expression**

165 To begin to understand the role of the TprA/PhrA cassette in *S. pneumoniae*, we  
166 constructed mutant strains that contained deletions of *tprA* or *phrA*. These deletion strains  
167 showed no significant deviation from wild-type during growth *in vitro* or virulence in a murine  
168 model for invasive disease, indicating that the deletion mutations do not alter the overall  
169 physiology of the bacteria (Figure S2). Many quorum sensing regulatory circuits, including those  
170 regulated by Phr peptides, contain positive feedback loops to rapidly increase expression of the  
171 genes that produce the signaling molecules ([Lazazzera et al., 1999](#), [Lereclus et al., 1996](#),  
172 [Kleerebezem et al., 1997](#)). To assess the activity of the TprA/PhrA system and whether *phrA*  
173 was regulated by the system, we constructed a *lacZ* transcriptional fusion to the promoter of  
174 *phrA* by fusing the intergenic region between *tprA* and *phrA* to *lacZ* and integrating this construct  
175 in single copy on the *S. pneumoniae* chromosome at *bgaA*. The gene construct results in the  
176 disruption of *bgaA*, which is the endogenous gene for  $\beta$ -galactosidase ([Halfmann et al., 2007](#)).  
177 During exponential growth in rich media, the levels of *phrA-lacZ* were low in the wild-type strain  
178 background are not statistically different from the levels in the  $\Delta$ *phrA* mutant (Figure 1A),  
179 indicating that the TprA/PhrA system was not active under these growth conditions. In the  $\Delta$ *tprA*  
180 strain background, *phrA* expression was elevated 34-fold relative to the wild-type strain (Figure  
181 1A). The increased expression of *phrA* was due to the absence of TprA as *phrA-lacZ* levels  
182 dropped back to wild-type levels in the complemented strain (i.e.  $\Delta$ *tprA* strain background with  
183 *tprA* at an ectopic locus) (Figure 1A). The same pattern of expression was seen when *phrA*  
184 expression levels were monitored directly using qRT-PCR in exponentially growing cells (Figure  
185 1B). These data indicate that TprA serves as an inhibitor of PhrA expression and that the  
186 TprA/PhrA system was not active during growth in rich media.  
187

188 **PhrA can induce expression of the TprA regulon by antagonizing TprA activity**

189           Next, we tested whether PhrA encodes a signaling peptide that can influence expression  
190 of the TprA-regulated genes. If PhrA were a co-inhibitor of the TprA regulon, an increase in  
191 *phrA-lacZ* expression would be expected in the  $\Delta phrA$  strain background, which was not  
192 observed (Figure 1A). Alternatively, PhrA could serve as an antagonist to TprA activity, and if so,  
193 we would expect to see an increase in *phrA-lacZ* in response to PhrA. To that end, full-length  
194 *phrA* was placed under the control of a fucose-inducible promoter ( $P_{fcsk}$ ), and this construct was  
195 integrated as a single copy in a strain that contained *phrA-lacZ*. We monitored the levels of  
196 *phrA-lacZ* in the presence and absence of fucose and found that *phrA-lacZ* levels were indeed  
197 increased in a statistically significant manner when PhrA was overexpressed (Figure 2A),  
198 indicating that PhrA can activate expression of the TprA regulon and participate in  
199 autoregulation.

200           Based on the work with Phr peptides in Bacilli ([Slamti & Lereclus, 2002](#), [Bouillaut et al.,](#)  
201 [2008](#), [Pottathil & Lazazzera, 2003](#)), we predicted that the active PhrA signaling peptide would  
202 be a small peptide derived from the C-terminus of the PhrA precursor protein. To see if such a  
203 peptide was capable of activating the TprA/PhrA system, we treated cells containing the *phrA-*  
204 *lacZ* reporter with a synthetic peptide corresponding to last 10 residues of PhrA. Expression of  
205 *phrA* was approximately 15-fold higher in the presence of this synthetic peptide compared to the  
206 levels obtained by addition of the peptide-resuspension buffer (Figure 2B-C). A similar 45-fold  
207 increase in *phrA* expression was measured by qRT-PCR of wild-type cells treated with the 10-  
208 residue peptide (Figure S3). To test whether the PhrA peptide acts through TprA, we examined  
209 levels of the *phrA-lacZ* reporter in a  $\Delta tprA$  background. In the presence and absence of the 10-  
210 residue synthetic peptide, the levels of *phrA* expression were high in the absence of TprA  
211 (Figure 2C). Taken together, these data show that PhrA can induce expression of TprA-  
212 regulated genes, ostensibly by antagonizing the inhibitory activity of TprA.

213

#### 214 **Identification of the minimal peptide form of the PhrA signaling peptide**

215           To begin to elucidate the nature of the mature PhrA signaling peptide, we took two  
216 complementary approaches. First, we overexpressed PhrA proteins that lacked various portions  
217 of the C-terminus. If all or part of the mature peptide were located in the deleted portions of  
218 *phrA*, we would not observe induction of *phrA-lacZ*. Constructs of *phrA*, under the control of  
219  $P_{fcsK}$ , were created that lacked the last 15, 10, 5 or 1 residues of PhrA (PhrA $\Delta$ 42-56, PhrA $\Delta$ 47-  
220 56, PhrA $\Delta$ 52-56, and PhrA $\Delta$ 56, respectively). Each of these truncated proteins failed to induce  
221 *phrA-lacZ* (Figure 2A), consistent with idea that the mature signaling peptide is derived from the  
222 very C-terminus of the precursor protein. Additionally, cells treated with 5  $\mu$ M of synthetic  
223 peptides corresponding to the last 6, 7, or 10 residues of PhrA resulted in induction of *phrA*-  
224 *lacZ*. In contrast, treatment with synthetic peptides corresponding to the last 5 residues or a 6-  
225 residue internal fragment (i.e. the active 7-residue peptide but lacking the very last aspartic acid)  
226 did not induce *phrA-lacZ* (Figure 2C). These data demonstrate that the minimal peptide  
227 corresponds to the very C-terminal 6 amino acids of PhrA. Interestingly, the longer synthetic 7-  
228 and 10-residue PhrA peptides showed a greater ability to induce system activity (Figure 2C).  
229 Thus, the mature PhrA peptide produced by cells could be longer than the minimal 6-residue  
230 peptide identified in this study.

231

#### 232 **Oligopeptide permease is required for cells to respond to the synthetic PhrA peptide**

233           Internalization of the extracellular PhrA-signaling peptide is central to the mechanism  
234 whereby the extracellular PhrA peptide signals to cells by interacting directly with TprA. Thus,  
235 we asked whether the oligopeptide permease encoded by *amiABCDE* of *S. pneumoniae* is  
236 required for responding to the PhrA-signaling peptide. To this end, expression of *phrA-lacZ* was  
237 measured in a strain that lacked *amiC* in the presence and absence of the 10-residue synthetic

238 PhrA peptide (Figure 3). Expression of *phrA* in the strain deleted for  $\Delta$ *amiC* was low and  
239 indistinguishable from isogenic wild-type cells in the absence of peptide, but failed to show  
240 induction in response to PhrA peptide treatment. A simple model for the role of Opp is to import  
241 the PhrA peptide into the cell to antagonize TprA activity. Consistent with this model, *phrA-lacZ*  
242 expression increased 21-fold in the strain lacking both *amiC* and *tprA*, as compared to the strain  
243 just lacking *amiC*, and reached a level of expression comparable to the *tprA* mutant strain  
244 (Figure 3). As expected, the strain lacking *amiC* and *tprA* was unable to respond to the 10-  
245 residue PhrA peptide. These data are in agreement with Opp functioning upstream of TprA to  
246 transport mature PhrA peptide into the cell to antagonize TprA control of gene expression.  
247

248 **The TprA/PhrA system is active in media containing galactose.**

249           During growth under laboratory conditions in rich media, the TprA/PhrA signaling system  
250 is not active (Figure 1). The promoter for *phrA* is predicted to contain a CRE element for binding  
251 the carbon-catabolite repressor CcpA in *S. pneumoniae*, and expression of both *tprA* and *phrA*  
252 were found to be elevated in a  $\Delta ccpA$  background in a microarray study ([Carvalho et al., 2011](#)).  
253 These data suggest that the lack of activity for the TprA/PhrA system in the rich BHI media may  
254 be due to the inhibitory effects of glucose in the formulated Becton-Dickinson BHI media as  
255 it contains 0.2 % glucose in this media. Thus, we examined *phrA-lacZ* activity when cells  
256 were grown in chemically defined media made with either glucose or galactose as the sole  
257 carbon source (CDM-glucose or CDM-galactose, respectively) (Figure 4A). When cells  
258 containing the *phrA-lacZ* reporter were grown in CDM-glucose, the activity of the reporter  
259 remained very low throughout the growth curve (Figure 4B). However, when the same cells  
260 were grown in CDM-galactose, expression of the reporter was induced during mid-exponential  
261 growth and continued to increase throughout the growth of the culture as expected for a cell  
262 density monitoring system (Figure 4A & B). Similar results for *phrA* expression were observed  
263 by qRT-PCR (Figure S4). These data indicate that the TprA/PhrA system is active in cells grown  
264 in the presence of galactose, but not glucose.

265           As *phrA* expression was induced when cells were grown in CDM-galactose, we asked if  
266 a PhrA signaling peptide was produced and exported in this same media. Wild-type cells  
267 containing *phrA-lacZ* were grown in CDM-galactose to exponential phase ( $OD_{620} \sim 0.1$ ) when  
268 they were collected by centrifugation and resuspended in CDM-galactose media conditioned by  
269 the growth of wild-type cells (WT CM) or  $\Delta phrA$  mutant cells ( $\Delta phrA$  CM). As a control, these  
270 cells were also resuspended in the original CDM-galactose growth media (untreated).  
271 Incubation of cells with WT CM resulted in a strong induction of *phrA-lacZ* after 4 hours, which  
272 was significantly higher than the induction observed with the untreated media. The inducing

273 activity of the conditioned media was dependent on PhrA, as  $\Delta phrA$  CM did not induce *phrA*-  
274 *lacZ* (Figure 4C). These data indicate that a mature PhrA signaling peptide was present in the  
275 conditioned media from wild-type cells and that this signaling peptide is able to activate the TprA  
276 regulon when added to cells in trans.  
277

## 278 **TprA and PhrA regulate lantibiotic biosynthesis machinery**

279 TprA is predicted to be a transcription factor, and thus, to begin to identify genes  
280 controlled by the TprA/PhrA quorum sensing system in *S. pneumoniae*, we performed whole-  
281 genome expression profiling using RNA-sequencing (RNA-seq) on cells lacking *tprA*, *phrA* or  
282 both, and on cells treated with 10-residue synthetic PhrA peptide (PhrA(10)). RNA was isolated  
283 from  $\Delta tprA$  cells,  $\Delta phrA$  cells, and  $\Delta(tprA-phrA)$  cells and compared to RNA isolated from wild-  
284 type cells, and RNA isolated from wild-type cells treated with 10  $\mu$ M peptide was compared to  
285 RNA isolated from cells lacking peptide treatment. Genes that were significantly differentially  
286 expressed were identified as those that had an up- or down-fold change of at least 2.0 with a  
287 false detection rate of 0.001 or lower (Table 1). Transcript levels for *tprA* (spd1745) and *phrA*  
288 (spd1746) were increased on average 10- and 28-fold, respectively, in cells lacking *tprA* or  
289 induced with PhrA(10). While *tprA* was only identified to be induced in cells treated with  
290 PhrA(10), *tprA* was not identified as differentially expressed in the strains  $\Delta tprA$  and  $\Delta(tprA-$   
291 *phrA) in Table 1. In strains with a deletion of *tprA* mutant, we observed an increase of  
292 transcription just 5' to the location of the *tprA* deletion (Figure S6), indicating that TprA  
293 negatively regulates its own expression. However, due to the lack of *tprA* transcription in the  
294 deleted region, the total sum of reads was below the 2-fold difference threshold through *tprA* in  
295 the  $\Delta tprA$  or  $\Delta(tprA-phrA)$  mutant strains compared to the wild-type strain. Thus, these data  
296 revealed *tprA* and *phrA* are transcribed divergently and autoregulate their own production.*



297 Besides *phrA* and *tprA*, 22 genes were found to be differentially expressed in at least  
298 one of the mutant strains or cells treated with PhrA(10) (Table 1). Eleven of these genes flank  
299 the *tprA*, *phrA* region and were differentially expressed to similar extents in both the PhrA(10)-  
300 treated cells, as well as the  $\Delta tprA$  single and  $\Delta(tprA-phrA)$  double mutants (Table 1; Figure 5).  
301 None of these genes was differentially expressed in the  $\Delta phrA$  mutant, consistent with the levels  
302 of *phrA* expression in wild-type cells being insufficient to activate expression of these genes.  
303 Four genes, extending from *spd0769* to *spd0773* were all up-regulated in PhrA(10)-treated cells  
304 and in the  $\Delta(tprA-phrA)$  mutant, with the exception of *spd0769* that was only induced in the  
305 PhrA(10)-treated cells. Why these genes were not also induced in either the  $\Delta tprA$  or  $\Delta phrA$   
306 single mutant is unknown. The remaining seven genes were only regulated under one of the  
307 conditions tested. While these genes controlled by one or two of the conditions tested are  
308 potentially interesting, we choose to focus on the genes, *spd1744* to *spd1756*, consistently  
309 identified as differentially expressed under conditions of PhrA(10) treatment or loss of *tprA* (i.e.  
310 the single  $\Delta tprA$  or double  $\Delta(tprA-phrA)$  mutant).

311           Of the thirteen genes extending from spd1744 to spd1756, at least nine of these genes  
312 (spd1747 to spd1755) are predicted to be involved in synthesis of or immunity to a lantibiotic  
313 peptide (Figure 5, Table 1). All of the genes in this region were upregulated in strains lacking  
314 *tprA* at least 3-fold and as much as 50-fold over the levels found in the wild-type strain, and  
315 were induced to a slightly lesser extent in the presence of the PhrA peptide. Four promoters are  
316 predicted in this region from RNA-seq data of the wild-type strain by comparing expression  
317 levels of neighboring genes (data not shown) (Figure 5). One of these predicted promoters is  
318 upstream of spd1744, a gene of unknown function. A second promoter is located upstream of  
319 *tprA*, which is predicted to be in a single gene operon, and this promoter most likely contributes  
320 to its autoregulation. A third promoter is located upstream of *phrA*, which is predicted to be in  
321 an operon with spd1747 and spd1748, which encode lantipeptide precursor proteins. The last  
322 promoter is located upstream of spd1754, which appears to be in an operon with spd1755 and  
323 possibly spd1756, and encodes a putative lantipeptide transporter, an immunity protein, and a  
324 protein of unknown function, respectively. The genes extending from spd1749 to spd1753,  
325 which encode putative lantipeptide modifying enzymes, were expressed at levels that were  
326 below the threshold for promoter prediction in the wild-type strain. However, the DOOR  
327 database for predicted operons ([Mao et al., 2009](#)) indicates that potential promoters are  
328 upstream of spd1749 and spd1750. We were unable to identify any conserved inverted repeats  
329 in the putative promoter regions (see Supplemental Material and Methods). Thus, the binding-  
330 site for TprA is unknown, and future research is necessary to identify its binding site.

331           To validate the RNA-seq data, qRT-PCR was performed to confirm the regulation by the  
332 TprA on several of the key lantibiotic biosynthesis genes: the lantibiotic precursor peptides,  
333 spd1747 and spd1748 (these genes were probed together in the qRT-PCR analysis due to their  
334 small size), the bifunctional modification enzyme encoding by spd1749, a second predicted  
335 lantibiotic biosynthesis enzyme encoded by spd1750, and the gene that encodes the predicted  
336 immunity protein, spd1754 (Figure 5). RNA from wild-type,  $\Delta tprA$  and  $\Delta tprA$ -complemented

337 strains were isolated from mid-exponentially growing cells and subjected to qRT-PCR analysis.  
338 TprA-dependent inhibition of expression was observed for all 4 sets of genes as probe levels  
339 increased significantly in the  $\Delta tprA$  strain compared to wild-type and dropped again to near-wild-  
340 type levels in the  $\Delta tprA$ -complemented strain (Figure S5).

341 To confirm that the extracellular PhrA peptide could also activate expression of the  
342 lantibiotic machinery, we performed qRT-PCR analysis for these same 4 sets of genes on RNA  
343 isolated from mid-exponential wild-type cells that had been treated with the synthetic 10-residue  
344 PhrA peptide. Again, we observed significant upregulation of all 4 sets of genes in the cells that  
345 were treated with the synthetic peptide compared to those that had been treated with the  
346 peptide-resuspension buffer alone (Figure S5). The data from the RNA-seq analysis and  
347 subsequent validation of the regulation of several key lantibiotic genes by qRT-PCR indicate  
348 that the TprA/PhrA signaling system controls expression of the adjacent putative lantibiotic  
349 biosynthesis gene cluster. **DISCUSSION**

350 We report here the identification and characterization of a new quorum-sensing cassette  
351 in *S. pneumoniae* D39 that belongs to the Phr family of quorum-sensing systems, which had  
352 previously only been identified in Gram-positive, endospore-forming bacteria. Through RNA-  
353 seq analysis, the PhrA peptide was found to induce genes that appear to process and provide  
354 immunity to a lantibiotic peptide. The expression of *phrA* and the corresponding lantibiotic  
355 genes were shown to be inhibited by the presence of glucose and to be induced in the presence  
356 of galactose. Galactose is the major sugar in the human nasopharynx ([King, 2010](#), [Yesilkaya et al., 2008](#)), consistent with a role for TprA/PhrA and the lantibiotic peptide in colonization of the  
357 host.

359 Lantibiotics are highly modified peptides that fall in the bacteriocin family of small  
360 antimicrobial peptides produced by many bacterial species and have been implicated in inter-  
361 and intra-species competition. These peptides are ribosomally synthesized and can have broad-  
362 or narrow-spectrum antimicrobial activity against other bacteria ([Cotter et al., 2005](#), [Cotter et al., 2013](#)). *S. pneumoniae* is already known to produce the Blp bacteriocin that is responsible for  
363 mediating intra-species competition amongst a few *S. pneumoniae* clinical isolates during host  
364 nasopharynx colonization ([Dawid et al., 2007](#)). Antibacterial activity of the lantibiotic system  
365 controlled by pneumococcal TprA/PhrA was suggested by experiments in a heterologous  
366

367 system. When the two lantibiotic-precursor peptides from *S. pneumoniae* were produced and  
368 modified using the nisin machinery from *Lactococcus lactus*, the peptides exhibited antimicrobial  
369 activity against *Micrococcus flavus*, an organism that colonizes humans ([Majchrzykiewicz et al.,](#)  
370 [2010](#)). Given the necessity for inter- as well as intra-species competition during nasopharynx  
371 colonization, lantibiotic biosynthesis machinery may represent a mechanism for interspecies  
372 competition in the nasopharynx. At this time, we cannot rule out other possible functions for the  
373 lantibiotic gene cluster, spd1744-spd1756. Lantipeptides produced by *Streptomyces* spp. have  
374 surfactant activity and are used to reduce surface tension for aerial hyphae formation ([Willey &](#)  
375 [van der Donk, 2007](#), [Kodani et al., 2004](#), [Kodani et al., 2005](#)). Surfactants have also been  
376 implicated in biofilm formation in a number of bacterial species ([Otto, 2013](#), [Raaijmakers et al.,](#)  
377 [2010](#)), and biofilm formation has recently been implicated in colonization of the nasopharynx by  
378 *S. pneumoniae* ([Munoz-Elias et al., 2008](#), [Marks et al., 2012a](#), [Marks et al., 2012b](#)).  
379 Experiments are currently underway to identify the biological role for this lantibiotic biosynthesis  
380 gene cluster.

381         A model for the mechanism by which TprA/PhrA induce the lantibiotic biosynthesis gene  
382 cluster is presented in Figure 6. The PhrA signaling peptide is derived from a precursor protein  
383 that is predicted to be exported through the Sec pathway and processed outside the cell by  
384 proteases to release the mature peptide, whose minimal form is the C-terminal 6 residues of the  
385 PhrA-precursor protein. Once the PhrA peptide has reached a sufficient extracellular  
386 concentration, it interacts with Opp whereby it is predicted to be brought into the cytoplasm and  
387 antagonize the inhibitory activity of TprA to induce expression of the peptide-encoding gene  
388 itself, *tprA*, and the lantibiotic biosynthesis gene cluster. At this time, we cannot rule out that  
389 TprA and/or PhrA may control more genes than those identified through the growth condition  
390 used in this study. Consistent with this possibility, the *tprA/phrA* genes are highly conserved in  
391 other *S. pneumoniae* serotype strains, but the lantibiotic biosynthetic cluster genes are not.

392 We found that the TprA/PhrA system is active and capable of signaling between cells  
393 when grown in media that contains galactose, but not glucose. The differential expression of  
394 these genes in response to glucose versus galactose appears to be mediated via the canonical,  
395 carbon catabolite control mechanism of Gram-positive bacteria, in which the CcpA protein binds  
396 to CRE elements in promoters when cells are grown in the presence of glucose ([Sonenshein,  
397 2007](#)). The promoter for *phrA* is predicted to contain a CRE-binding site for the pneumococcal  
398 CcpA ([Carvalho et al., 2011](#)). In this context, it is interesting to note that genes involved in sugar  
399 metabolism, including PTS system components (e.g. spd0771-0773), were differentially  
400 expressed in PhrA peptide treated cells, but the significance of this regulation is unknown as a  
401  $\Delta tprA$  mutation did not significantly induce the expression of these same genes. The expression  
402 levels for *tprA*, *phrA*, and many members of the putative lantibiotic biosynthesis gene cluster  
403 were upregulated in a strain that lacked CcpA compared to a wild-type strain when the cells  
404 were grown in the presence of glucose ([Carvalho et al., 2011](#)). Expression of the lantibiotic  
405 gene cluster has also been shown to be inhibited by the CiaRH two-component regulatory  
406 system ([Mascher et al., 2003](#)); although at this time there is no data to suggest that CiaRH  
407 mediates catabolite control of this gene cluster. These data indicate that the production of the  
408 lantibiotic biosynthesis machinery is part of the carbon-catabolite response of *S. pneumoniae*,  
409 and is the first example, to our knowledge, of a lantibiotic incorporated into the carbon-catabolite  
410 regulon.

411 The differential regulation of the TprA-regulon based on available carbon source is  
412 interesting when placed in the context of where the pneumococcal cells may encounter glucose  
413 or galactose in the human host. Glucose is the preferred carbon source for pneumococcal cells  
414 and found in large amounts in the bloodstream and respiratory tract of the host, areas which are  
415 normally low in bacterial counts ([Philips et al., 2003](#)). Galactose, in contrast, is one of the main  
416 carbon sources that pneumococcal cells encounter in the nasopharynx during colonization  
417 where they need to compete with other strains of *S. pneumoniae* and other bacterial species for

418 space and resources ([King, 2010](#), [Yesilkaya et al., 2008](#)). These data are consistent with recent  
419 Tn-Seq analysis that showed that transposon insertions in *tprA* or in some of the genes of the  
420 lantibiotic biosynthesis operon significantly reduced the fitness of *S. pneumoniae* serotype 4  
421 strain TIGR4 for nasopharynx colonization in a murine model ([van Opijnen & Camilli, 2012](#)).  
422 Thus, the TprA/PhrA system and its controlled lantibiotic genes are important for *S. pneumoniae*  
423 to colonize the nasopharynx.

424 Consistent with a role for the TprA/PhrA system in colonization is the finding that these  
425 genes and the lantibiotic gene cluster are not required for invasive disease. The Tn-Seq study  
426 previously mentioned did not detect a role for the TprA/PhrA system in murine model of invasive  
427 disease ([van Opijnen & Camilli, 2012](#)). Likewise, we found that deletion of either *tprA* or *phrA*  
428 has no overt effect on a murine pneumonia model (Fig S2). Consistent with the lack of a role for  
429 antimicrobial activity during invasive disease by *S. pneumoniae*, others have observed that Blp  
430 bacteriocin production is down regulated in mice during invasive pneumococcal disease  
431 compared to growth *in vitro* ([Orihuela et al., 2004](#)).

432 In order to effectively combat pneumococcal disease, a detailed understanding of the  
433 mechanisms that mediate *S. pneumoniae* inter- and intra-species interactions is essential, yet  
434 little is known about the genetic and molecular basis for these exchanges. The TprA/PhrA  
435 quorum sensing system control of lantibiotic production may be one method employed by  
436 pneumococcal cells to ensure competitive fitness during colonization of the human host. Further  
437 characterization of this system will increase our understanding of pneumococcal colonization  
438 and possibly lead to new targets for antimicrobial therapies.

## 439 **EXPERIMENTAL PROCEDURES**

### 440 **Bacterial strains and growth conditions**

441           Strains used in this study are derivatives of encapsulated, virulent serotype 2 strain D39  
442 (Table S5). Details of mutant strains and constructs generated for this work are found in the  
443 *Supplemental Information*. Pneumococcal strains were grown at 37°C with 5% CO<sub>2</sub>, either on  
444 Trypticase Soy Agar II plates (modified; Becton-Dickinson) with 5% (vol/vol) defibrinated sheep  
445 blood (TSAll-BA), in Becton-Dickinson brain heart infusion (BHI) broth, or in chemically defined  
446 media ([Kazmierczak et al., 2009](#)) with 1% glucose (wt/vol) (CDM-glucose) or 1% (wt/vol)  
447 galactose (CDM-galactose) as the sole carbon source. Liquid cultures were grown statically  
448 and monitored by optical density at 620 nm (OD<sub>620</sub>) using a Spectronic 20 or a Teysche 100  
449 spectrophotometer. Starter cultures of pneumococcal strains were inoculated from frozen  
450 glycerol stocks into BHI broth, serial diluted in the same media, and propagated for 8-16 hours.  
451 For growth in BHI broth, starter cultures still in exponential phase (OD<sub>620</sub> of 0.1 to 0.4) were  
452 diluted to an OD<sub>620</sub> of 0.002 to 0.005 to start final cultures. For the overexpression of PhrA, the  
453 final cultures were grown in BHI broth that contained 1% (wt/vol) L-fucose. For growth in CDM-  
454 glucose and CDM-galactose, the cells of starter cultures were collected by microcentrifugation  
455 at 3000 x g for 10 minutes at room temperature. The cells were washed, resuspended, and  
456 diluted in CDM-glucose or CDM-galactose to an OD<sub>620</sub> of 0.001 to 0.005 to start final cultures.  
457 For antibiotic selections, TSAll-BA plates or BHI broth cultures were supplemented with 0.3  
458 µg/ml erythromycin, 250 µg/ml kanamycin, 250 µg/ml streptomycin, or 0.25 µg/ml tetracycline.  
459



460  **$\beta$ -galactosidase assays**

461  $\beta$ -galactosidase specific activity ( $[A_{420}$  per min per ml of culture per  $OD_{620}] \times 1,000$ ) was  
462 determined essentially as described previously ([Hoover et al., 2010](#)), except that cell lysis was  
463 achieved by incubating cells in lysis buffer containing TritonX-100 to induce autolysis as in  
464 ([Zahner & Hakenbeck, 2000](#)). Conditioned media for use in these assays was produced by  
465 culturing *S. pneumoniae* strains in CDM-galactose to a high cell density ( $OD_{620}$  of  $> 1.0$ ),  
466 removing the cells by centrifugation at  $7000 \times g$  for 5 minutes at room temperature, and  
467 sterilization of the supernatant through  $0.22 \mu\text{m}$  filters. For the assays in conditioned media, 30  
468 mL cultures of exponentially growing cells ( $OD_{620}$  of  $\sim 0.3$ ) were divided into 6 mL aliquots, the  
469 cells collected by centrifugation at  $7000 \times g$  at room temperature for 5 minutes, and the cell  
470 pellets resuspended in the appropriate conditioned media. Samples were removed at the  
471 indicated time for  $\beta$ -galactosidase assays. Reporter construct expression was compared as  
472 indicated by performing unpaired two-tailed t tests.

473

474 **RNA extraction**

475 To isolate RNA for qRT-PCR analysis, starter cultures were used to inoculate 6 ml  
476 cultures of BHI broth or CDM-galactose. RNA was extracted from 4 mL of exponentially growing  
477 cultures (OD<sub>620</sub> of ~0.2) using a hot-lysis, acid-phenol extraction followed by purification using an  
478 RNeasy minikit (Qiagen) and on-column DNase I treatment as described in ([Barendt et al.,](#)  
479 [2009](#), [Kazmierczak et al., 2009](#), [Ramos-Montanez et al., 2008](#)). 5 µg of total RNA was further  
480 digested with DNase using a DNA-free kit (Ambion) prior to qRT-PCR analysis. To isolate RNA  
481 for RNA-sequencing analysis, starter cultures were used to inoculate 30 ml cultures of BHI broth  
482 in 50 mL conical tubes. RNA was extracted from 23 mL of exponentially growing culture (OD<sub>620</sub>  
483 of ~0.15) using the FastRNA Pro Blue Kit (MP Bio) according to the manufacturer's guidelines.  
484 Briefly, cells were isolated by centrifugation at 14,500 x g for 5 minutes at 4°C. The cells were  
485 resuspended in 1 ml RNApro (MP Bio) and processed twice in the Fast Prep Instrument (MP  
486 Bio) for 40 seconds at a setting of 6.0. Chloroform and 100% ethanol were used to extract and  
487 precipitate the RNA from the resulting lysate and the miRNeasy minikit (Qiagen) and on-column  
488 DNase I treatments were used to purify the RNA as above. The amount and purity of all RNA  
489 samples isolated were assessed by NanoDrop spectroscopy (Thermo Fisher). RNA integrity  
490 was assessed using the Agilent 2100 BioAnalyzer (Aligent Technologies).

491

#### 492 **qRT-PCR**

493 qRT-PCR was performed using a two-step protocol as in ([Ramos-Montanez et al., 2008](#),  
494 [Kazmierczak et al., 2009](#)). Specifically, cDNA was synthesized from 100 ng of total RNA and  
495 random primers using the qScript Flex cDNA Kit (Quanta BioSciences). RT-PCR was performed  
496 using the Brilliant SYBR Green qPCR Master Mix (Stratagene), the Brilliant III Ultra-Fast SYBR  
497 Green qPCR Master Mix (Agilent), or the FastStart Universal SYBR Green Master Mix (Roche)  
498 and appropriate primers (see Table S6) as in ([Kazmierczak et al., 2009](#), [Ramos-Montanez et al.,](#)  
499 [2008](#)). Reactions were performed in duplicate and normalized to 16S rRNA amounts. The 16S  
500 rRNA was quantified using the same cDNA samples except that the samples were diluted 100-

501 fold further. Data were collected on an MX3000P thermocycler (Stratagene) or on a CFX96  
502 thermocycler (Bio Rad) and analyzed with the SYBR Green (with dissociation curve) program  
503 associated with each machine. Four dilutions of cDNA from *S. pneumoniae* strains wild-type for  
504 *tprA* and *phrA* (either IU1781 or Spn049) were used to generate standard curves for each  
505 primer set. Normalized transcript amounts were compared as indicated by performing pairwise  
506 unpaired two-tailed t tests.

507

### 508 **Synthetic peptides**

509 Peptides were synthesized on a modified Applied Biosystems 430A peptide synthesizer  
510 using 0.2 mmol of 4-hydroxymethyl-phenylacetamidomethyl (PAM) resin (Midwest Biotech) and  
511 subsequently purified using reverse phase HPLC (RP-HPLC). For complete details, see  
512 *Supplementary Information*. Synthetic peptides were resuspended in 10 mM Tris pH 7.4 with 50  
513 µg/ml BSA to a concentration of 5 mM. For β-galactosidase or qRT-PCR assays, the indicated  
514 synthetic peptide (or the peptide-resuspension buffer) was added at final concentration of 5 µM  
515 to each 6 ml cell aliquot.

516

### 517 **Library construction and RNA-sequencing**

518 cDNA libraries were prepared from total RNA by the University of Wisconsin-Madison  
519 Biotechnology Center. The mRNA was enriched from two micrograms total RNA using  
520 RiboZero™ rRNA Removal (Gram-positive bacteria) Kit (EpiCentre Inc.). rRNA-depleted mRNA  
521 samples were purified by ethanol precipitation and quantified by fluorometry with the Qubit®  
522 RNA assay kit (Invitrogen). Double stranded cDNA synthesis was performed following  
523 ScriptSeq™ v2 RNA-Seq Library Preparation guide (EpiCentre Inc.) in accordance with the  
524 manufacturer's standard protocol. Thirty nanograms of enriched mRNA were fragmented using  
525 divalent cations via incubation for 5 min at 85°C. The first strand of cDNA was synthesized by

526 reverse transcription using random-sequence primers containing a tagging sequence at their 5'  
527 ends. Di-tagged cDNA was synthesized by random annealing of a terminal-Tagging Oligo (TTO)  
528 to the 3' end of the cDNA for extension of the cDNA by DNA polymerase. Di-tagged cDNA was  
529 purified using Agencourt AMPure® XP beads (Beckman Coulter) followed by PCR amplification  
530 for 15 cycles using Failsafe™ PCR enzyme and ScriptSeq Index DNA primer set (EpiCentre  
531 Inc.). This step generated the second strand of cDNA and completed the addition of Illumina  
532 adapter sequences incorporating a user-defined barcode. The amplified libraries were purified  
533 using Agencourt AMPure® XP beads. Quality and quantity were assessed using an Agilent DNA  
534 1000 chip (Agilent) and Qubit® dsDNA HS assay kit (Invitrogen), respectively. Libraries were  
535 standardized to 2 µM. Cluster generation was performed using standard Cluster kits (v3) and  
536 Illumina Cluster Station. Single-end 100 bp sequencing was performed using standard SBS  
537 chemistry (v3) on an Illumina HiSeq2000 sequencer. Images were analyzed using the standard  
538 Illumina pipeline, version 1.8.2.

539

#### 540 **RNA-seq analysis**

541 The raw sequencing reads were quality and adapter trimmed using Trimmomatic ([Lohse](#)  
542 [et al., 2012](#)) with a minimum length of 90. The trimmed reads were mapped on the  
543 *Streptococcus pneumoniae* D39 (RefSeq NC\_008533) genome and D39 plasmid pDP1  
544 sequence (RefSeq NC\_005022) using bowtie2 ([Langmead & Salzberg, 2012](#)). Custom PERL  
545 scripts were used to generate read counts for the genes and 100 bp non-overlapping intergenic  
546 regions of the genome. Differential gene expression was identified using EdgeR (version 3.6.2)  
547 using default parameters ([Robinson et al., 2010](#)). The false discovery rate (FDR) was  
548 calculated using Benjamini and Hochberg's algorithm ([Benjamini & Hochberg, 1995](#)) and a gene  
549 or region was defined as differentially expressed if it had an up- or down-fold change of 2.0 and  
550 their FDR was less than 0.001.

551

552 **ACKNOWLEDGMENTS**

553           We thank Reinhold Brückner for pPP2, Kyle J. Wayne for bacterial strains, and John  
554 Lisher for instruction in CDM preparation. We thank Kurt Zimmer and Doug Rusch for  
555 assistance in analysis of RNA-seq data. We thank the members of the Lazazzera laboratory,  
556 members of the Winkler laboratory, and many generous colleagues for helpful discussions.

557           This work was supported by NIH grant AI48616 to B.A.L. and AI095814 and AI107075 to  
558 M.E.W. and by funds from the Indiana University Bloomington METACyt Initiative, funded in part  
559 by a major grant from the Lilly Endowment (M.E.W). S.E.H. was supported by an NIH  
560 postdoctoral training grant (5T32AI007323). A.J.P. was supported by an NIH IMSD grant  
561 (R25GM055052). The authors declare that they have no conflict of interest with the research  
562 presented.

## 563 REFERENCES

- 564 (2007) Pneumococcal conjugate vaccine for childhood immunization--WHO position paper.  
565 *Wkly Epidemiol Rec* **82**: 93-104.
- 566 Aceves-Diez, A.E., R. Robles-Burgueno & M. de la Torre, (2007) SKPDT is a signaling peptide  
567 that stimulates sporulation and cry1Aa expression in *Bacillus thuringiensis* but not in  
568 *Bacillus subtilis*. *Appl Microbiol Biotechnol*.
- 569 Alloing, G., C. Granadel, D.A. Morrison & J.P. Claverys, (1996) Competence pheromone,  
570 oligopeptide permease, and induction of competence in *Streptococcus pneumoniae*. *Mol*  
571 *Microbiol* **21**: 471-478.
- 572 Auchtung, J.M., C.A. Lee, R.E. Monson, A.P. Lehman & A.D. Grossman, (2005) Regulation of a  
573 *Bacillus subtilis* mobile genetic element by intercellular signaling and the global DNA  
574 damage response. *Proc Natl Acad Sci U S A* **102**: 12554-12559.
- 575 Barendt, S.M., A.D. Land, L.T. Sham, W.L. Ng, H.C. Tsui, R.J. Arnold & M.E. Winkler, (2009)  
576 Influences of capsule on cell shape and chain formation of wild-type and pcsB mutants  
577 of serotype 2 *Streptococcus pneumoniae*. *J Bacteriol* **191**: 3024-3040.
- 578 Benjamini, Y. & Y. Hochberg, (1995) Controlling the false discovery rate: a practical and  
579 powerful approach to multiple testing. *Journal of the Royal Statistical Society. Series B*  
580 *(Methodological)* **57**: 289-300.
- 581 Blomberg, C., J. Dagerhamn, S. Dahlberg, S. Browall, J. Fernebro, B. Albiger, E. Morfeldt, S.  
582 Normark & B. Henriques-Normark, (2009) Pattern of accessory regions and invasive  
583 disease potential in *Streptococcus pneumoniae*. *J Infect Dis* **199**: 1032-1042.
- 584 Bongiorno, C., S. Ishikawa, S. Stephenson, N. Ogasawara & M. Perego, (2005) Synergistic  
585 regulation of competence development in *Bacillus subtilis* by two Rap-Phr systems. *J*  
586 *Bacteriol* **187**: 4353-4361.
- 587 Bongiorno, C., R. Stoessel, D. Shoemaker & M. Perego, (2006) Rap phosphatase of virulence  
588 plasmid pXO1 inhibits *Bacillus anthracis* sporulation. *J Bacteriol* **188**: 487-498.
- 589 Bouillaut, L., S. Perchat, S. Arold, S. Zorrilla, L. Slamti, C. Henry, M. Gohar, N. Declerck & D.  
590 Lereclus, (2008) Molecular basis for group-specific activation of the virulence regulator  
591 PlcR by PapR heptapeptides. *Nucleic Acids Res* **36**: 3791-3801.
- 592 Brown, J.S., S.M. Gilliland, B.G. Spratt & D.W. Holden, (2004) A locus contained within a  
593 variable region of pneumococcal pathogenicity island 1 contributes to virulence in mice.  
594 *Infect Immun* **72**: 1587-1593.
- 595 Carvalho, S.M., T.G. Kloosterman, O.P. Kuipers & A.R. Neves, (2011) CcpA ensures optimal  
596 metabolic fitness of *Streptococcus pneumoniae*. *PLoS One* **6**: e26707.
- 597 Chang, J.C., B. LaSarre, J.C. Jimenez, C. Aggarwal & M.J. Federle, (2011) Two group A  
598 streptococcal peptide pheromones act through opposing Rgg regulators to control  
599 biofilm development. *PLoS Pathog* **7**: e1002190.
- 600 Chen, H., Y. Ma, J. Yang, C.J. O'Brien, S.L. Lee, J.E. Mazurkiewicz, S. Haataja, J.H. Yan, G.F.  
601 Gao & J.R. Zhang, (2008) Genetic requirement for pneumococcal ear infection. *PLoS*  
602 *One* **3**: e2950.
- 603 Claverys, J.P., B. Grossiord & G. Alloing, (2000) Is the Ami-AliA/B oligopeptide permease of  
604 *Streptococcus pneumoniae* involved in sensing environmental conditions? *Res Microbiol*  
605 **151**: 457-463.
- 606 Core, L. & M. Perego, (2003) TPR-mediated interaction of RapC with ComA inhibits response  
607 regulator-DNA binding for competence development in *Bacillus subtilis*. *Mol Microbiol* **49**:  
608 1509-1522.
- 609 Cotter, P.D., C. Hill & R.P. Ross, (2005) Bacteriocins: developing innate immunity for food. *Nat*  
610 *Rev Microbiol* **3**: 777-788.
- 611 Cotter, P.D., R.P. Ross & C. Hill, (2013) Bacteriocins - a viable alternative to antibiotics? *Nat*  
612 *Rev Microbiol* **11**: 95-105.

613 Cundell, D.R., B.J. Pearce, J. Sandros, A.M. Naughton & H.R. Masure, (1995) Peptide  
614 permeases from *Streptococcus pneumoniae* affect adherence to eucaryotic cells. *Infect*  
615 *Immun* **63**: 2493-2498.

616 Dawid, S., A.M. Roche & J.N. Weiser, (2007) The blp bacteriocins of *Streptococcus pneumoniae*  
617 mediate intraspecies competition both in vitro and in vivo. *Infection and immunity* **75**:  
618 443-451.

619 Dunny, G.M., (2007) The peptide pheromone-inducible conjugation system of *Enterococcus*  
620 *faecalis* plasmid pCF10: cell-cell signalling, gene transfer, complexity and evolution.  
621 *Philosophical transactions of the Royal Society of London* **362**: 1185-1193.

622 Fleuchot, B., C. Gitton, A. Guillot, J. Vidic, P. Nicolas, C. Besset, L. Fontaine, P. Hols, N.  
623 Leblond-Bourget, V. Monnet & R. Gardan, (2011) Rgg proteins associated with  
624 internalized small hydrophobic peptides: a new quorum-sensing mechanism in  
625 streptococci. *Molecular microbiology* **80**: 1102-1119.

626 Gohar, M., K. Faegri, S. Perchat, S. Ravnum, O.A. Okstad, M. Gominet, A.B. Kolsto & D.  
627 Lereclus, (2008) The PlcR virulence regulon of *Bacillus cereus*. *PLoS One* **3**: e2793.

628 Grenha, R., L. Slamti, M. Nicaise, Y. Refes, D. Lereclus & S. Nessler, (2013) Structural basis for  
629 the activation mechanism of the PlcR virulence regulator by the quorum-sensing signal  
630 peptide PapR. *Proc Natl Acad Sci U S A* **110**: 1047-1052.

631 Halfmann, A., R. Hakenbeck & R. Bruckner, (2007) A new integrative reporter plasmid for  
632 *Streptococcus pneumoniae*. *FEMS Microbiol Lett* **268**: 217-224.

633 Hava, D.L. & A. Camilli, (2002) Large-scale identification of serotype 4 *Streptococcus*  
634 *pneumoniae* virulence factors. *Mol Microbiol* **45**: 1389-1406.

635 Hoover, S.E., W. Xu, W. Xiao & W.F. Burkholder, (2010) Changes in DnaA-dependent gene  
636 expression contribute to the transcriptional and developmental response of *Bacillus*  
637 *subtilis* to manganese limitation in Luria-Bertani medium. *J Bacteriol* **192**: 3915-3924.

638 Huang, S.S., K.M. Johnson, G.T. Ray, P. Wroe, T.A. Lieu, M.R. Moore, E.R. Zell, J.A. Linder,  
639 C.G. Grijalva, J.P. Metlay & J.A. Finkelstein, (2011) Healthcare utilization and cost of  
640 pneumococcal disease in the United States. *Vaccine* **29**: 3398-3412.

641 Ishikawa, S., L. Core & M. Perego, (2002) Biochemical characterization of aspartyl phosphate  
642 phosphatase interaction with a phosphorylated response regulator and its inhibition by a  
643 pentapeptide. *J Biol Chem* **277**: 20483-20489.

644 Jimenez, J.C. & M.J. Federle, (2014) Quorum sensing in group A *Streptococcus*. *Frontiers in*  
645 *cellular and infection microbiology* **4**: 127.

646 Kazmierczak, K.M., K.J. Wayne, A. Rechtsteiner & M.E. Winkler, (2009) Roles of rel(Spn) in  
647 stringent response, global regulation and virulence of serotype 2 *Streptococcus*  
648 *pneumoniae* D39. *Mol Microbiol* **72**: 590-611.

649 Keller, L. & M.G. Surette, (2006) Communication in bacteria: an ecological and evolutionary  
650 perspective. *Nat Rev Microbiol* **4**: 249-258.

651 Kelley, L.A. & M.J. Sternberg, (2009) Protein structure prediction on the Web: a case study  
652 using the Phyre server. *Nat Protoc* **4**: 363-371.

653 King, S.J., (2010) Pneumococcal modification of host sugars: a major contributor to colonization  
654 of the human airway? *Mol Oral Microbiol* **25**: 15-24.

655 Kleerebezem, M., L.E. Quadri, O.P. Kuipers & W.M. de Vos, (1997) Quorum sensing by peptide  
656 pheromones and two-component signal-transduction systems in Gram-positive bacteria.  
657 *Mol Microbiol* **24**: 895-904.

658 Kodani, S., M.E. Hudson, M.C. Durrant, M.J. Buttner, J.R. Nodwell & J.M. Willey, (2004) The  
659 SapB morphogen is a lantibiotic-like peptide derived from the product of the  
660 developmental gene ramS in *Streptomyces coelicolor*. *Proc Natl Acad Sci U S A* **101**:  
661 11448-11453.

662 Kodani, S., M.A. Lodato, M.C. Durrant, F. Picart & J.M. Willey, (2005) SapT, a lanthionine-  
663 containing peptide involved in aerial hyphae formation in the streptomycetes. *Mol*  
664 *Microbiol* **58**: 1368-1380.

665 Langmead, B. & S.L. Salzberg, (2012) Fast gapped-read alignment with Bowtie 2. *Nat Methods*  
666 **9**: 357-359.

667 Lanigan-Gerdes, S., G. Briceno, A.N. Dooley, K.F. Faull & B.A. Lazazzera, (2008) Identification  
668 of residues important for cleavage of the extracellular signaling peptide CSF of *Bacillus*  
669 *subtilis* from its precursor protein. *J Bacteriol* **190**: 6668-6675.

670 Lanigan-Gerdes, S., A.N. Dooley, K.F. Faull & B.A. Lazazzera, (2007) Identification of subtilisin,  
671 Epr and Vpr as enzymes that produce CSF, an extracellular signalling peptide of *Bacillus*  
672 *subtilis*. *Mol Microbiol* **65**: 1321-1333.

673 Lazazzera, B.A., I.G. Kurtser, R.S. McQuade & A.D. Grossman, (1999) An autoregulatory circuit  
674 affecting peptide signaling in *Bacillus subtilis*. *J Bacteriol* **181**: 5193-5200.

675 Lazazzera, B.A., J.M. Solomon & A.D. Grossman, (1997) An exported peptide functions  
676 intracellularly to contribute to cell density signaling in *B. subtilis*. *Cell* **89**: 917-925.

677 Lereclus, D., H. Agaisse, M. Gominet, S. Salamiou & V. Sanchis, (1996) Identification of a  
678 *Bacillus thuringiensis* gene that positively regulates transcription of the  
679 phosphatidylinositol-specific phospholipase C gene at the onset of the stationary phase.  
680 *J Bacteriol* **178**: 2749-2756.

681 Lohse, M., A.M. Bolger, A. Nagel, A.R. Fernie, J.E. Lunn, M. Stitt & B. Usadel, (2012) RobiNA: a  
682 user-friendly, integrated software solution for RNA-Seq-based transcriptomics. *Nucleic*  
683 *Acids Res* **40**: W622-627.

684 Lyon, G.J. & R.P. Novick, (2004) Peptide signaling in *Staphylococcus aureus* and other Gram-  
685 positive bacteria. *Peptides* **25**: 1389-1403.

686 Majchrzykiewicz, J.A., J. Lubelski, G.N. Moll, A. Kuipers, J.J. Bijlsma, O.P. Kuipers & R. Rink,  
687 (2010) Production of a class II two-component lantibiotic of *Streptococcus pneumoniae*  
688 using the class I nisin synthetic machinery and leader sequence. *Antimicrob Agents*  
689 *Chemother* **54**: 1498-1505.

690 Mao, F., P. Dam, J. Chou, V. Olman & Y. Xu, (2009) DOOR: a database for prokaryotic operons.  
691 *Nucleic Acids Res* **37**: D459-463.

692 Marks, L.R., G.I. Parameswaran & A.P. Hakansson, (2012a) Pneumococcal interactions with  
693 epithelial cells are crucial for optimal biofilm formation and colonization in vitro and in  
694 vivo. *Infect Immun* **80**: 2744-2760.

695 Marks, L.R., R.M. Reddinger & A.P. Hakansson, (2012b) High levels of genetic recombination  
696 during nasopharyngeal carriage and biofilm formation in *Streptococcus pneumoniae*.  
697 *MBio* **3**.

698 Mascher, T., D. Zahner, M. Merai, N. Balmelle, A.B. de Saizieu & R. Hakenbeck, (2003) The  
699 *Streptococcus pneumoniae* cia regulon: CiaR target sites and transcription profile  
700 analysis. *J Bacteriol* **185**: 60-70.

701 Mirouze, N., V. Parashar, M.D. Baker, D.A. Dubnau & M.B. Neiditch, (2011) An atypical Phr  
702 peptide regulates the developmental switch protein RapH. *J Bacteriol* **193**: 6197-6206.

703 Molzen, T.E., P. Burghout, H.J. Bootsma, C.T. Brandt, C.E. van der Gaast-de Jongh, M.J.  
704 Eleveld, M.M. Verbeek, N. Frimodt-Moller, C. Ostergaard & P.W. Hermans, (2011)  
705 Genome-wide identification of *Streptococcus pneumoniae* genes essential for bacterial  
706 replication during experimental meningitis. *Infect Immun* **79**: 288-297.

707 Munoz-Elias, E.J., J. Marcano & A. Camilli, (2008) Isolation of *Streptococcus pneumoniae*  
708 biofilm mutants and their characterization during nasopharyngeal colonization. *Infection*  
709 *and immunity* **76**: 5049-5061.

710 O'Brien, K.L., L.J. Wolfson, J.P. Watt, E. Henkle, M. Deloria-Knoll, N. McCall, E. Lee, K.  
711 Mulholland, O.S. Levine & T. Cherian, (2009) Burden of disease caused by



712 Streptococcus pneumoniae in children younger than 5 years: global estimates. *Lancet*  
713 **374**: 893-902.

714 Obert, C., J. Sublett, D. Kaushal, E. Hinojosa, T. Barton, E.I. Tuomanen & C.J. Orihuela, (2006)  
715 Identification of a Candidate Streptococcus pneumoniae core genome and regions of  
716 diversity correlated with invasive pneumococcal disease. *Infect Immun* **74**: 4766-4777.

717 Ogura, M., K. Shimane, K. Asai, N. Ogasawara & T. Tanaka, (2003) Binding of response  
718 regulator DegU to the aprE promoter is inhibited by RapG, which is counteracted by  
719 extracellular PhrG in *Bacillus subtilis*. *Mol Microbiol.* **49**: 1685-1697.

720 Orihuela, C.J., J.N. Radin, J.E. Sublett, G. Gao, D. Kaushal & E.I. Tuomanen, (2004) Microarray  
721 analysis of pneumococcal gene expression during invasive disease. *Infection and*  
722 *immunity* **72**: 5582-5596.

723 Otto, M., (2013) Staphylococcal infections: mechanisms of biofilm maturation and detachment  
724 as critical determinants of pathogenicity. *Annual review of medicine* **64**: 175-188.

725 Parashar, V., P.D. Jeffrey & M.B. Neiditch, (2013) Conformational change-induced repeat  
726 domain expansion regulates Rap phosphatase quorum-sensing signal receptors. *PLoS*  
727 *biology* **11**: e1001512.

728 Perego, M., (1997) A peptide export-import control circuit modulating bacterial development  
729 regulates protein phosphatases of the phosphorelay. *Proc Natl Acad Sci USA* **94**: 8612-  
730 8617.

731 Perego, M. & J.A. Brannigan, (2001) Pentapeptide regulation of aspartyl-phosphate  
732 phosphatases. *Peptides* **22**: 1541-1547.

733 Perego, M. & J.A. Hoch, (1996) Cell-cell communication regulates the effects of protein  
734 aspartate phosphatases on the phosphorelay controlling development in *Bacillus subtilis*.  
735 *Proc Natl Acad Sci USA* **93**: 1549-1553.

736 Philips, B.J., J.X. Meguer, J. Redman & E.H. Baker, (2003) Factors determining the appearance  
737 of glucose in upper and lower respiratory tract secretions. *Intensive Care Med* **29**: 2204-  
738 2210.

739 Pomerantsev, A.P., O.M. Pomerantseva, A.S. Camp, R. Mukkamala, S. Goldman & S.H. Leppla,  
740 (2009) PapR peptide maturation: role of the NprB protease in *Bacillus cereus* 569  
741 PlcR/PapR global gene regulation. *FEMS Immunol Med Microbiol* **55**: 361-377.

742 Pottathil, M. & B.A. Lazazzera, (2003) The extracellular Phr peptide-Rap phosphatase signaling  
743 circuit of *Bacillus subtilis*. *Front Biosci* **8**: d32-45.

744 Raaijmakers, J.M., I. De Bruijn, O. Nybroe & M. Ongena, (2010) Natural functions of  
745 lipopeptides from *Bacillus* and *Pseudomonas*: more than surfactants and antibiotics.  
746 *FEMS Microbiol Rev* **34**: 1037-1062.

747 Ramos-Montanez, S., H.C. Tsui, K.J. Wayne, J.L. Morris, L.E. Peters, F. Zhang, K.M.  
748 Kazmierczak, L.T. Sham & M.E. Winkler, (2008) Polymorphism and regulation of the  
749 spxB (pyruvate oxidase) virulence factor gene by a CBS-HotDog domain protein (SpXR)  
750 in serotype 2 *Streptococcus pneumoniae*. *Mol Microbiol* **67**: 729-746.

751 Robinson, M.D., D.J. McCarthy & G.K. Smyth, (2010) edgeR: a Bioconductor package for  
752 differential expression analysis of digital gene expression data. *Bioinformatics* **26**: 139-  
753 140.

754 Rocha-Estrada, J., A.E. Aceves-Diez, G. Guarneros & M. de la Torre, (2010) The RNPP family  
755 of quorum-sensing proteins in Gram-positive bacteria. *Appl Microbiol Biotechnol* **87**: 913-  
756 923.

757 Rutherford, S.T. & B.L. Bassler, (2012) Bacterial quorum sensing: its role in virulence and  
758 possibilities for its control. *Cold Spring Harb Perspect Med* **2**.

759 Sastalla, I., L.M. Maltese, O.M. Pomerantseva, A.P. Pomerantsev, A. Keane-Myers & S.H.  
760 Leppla, (2010) Activation of the latent PlcR regulon in *Bacillus anthracis*. *Microbiology*  
761 **156**: 2982-2993.

- 762 Slamti, L. & D. Lereclus, (2002) A cell-cell signaling peptide activates the PlcR virulence regulon  
763 in bacteria of the *Bacillus cereus* group. *Embo J* **21**: 4550-4559.
- 764 Slamti, L. & D. Lereclus, (2005) Specificity and polymorphism of the PlcR-PapR quorum-  
765 sensing system in the *Bacillus cereus* group. *J Bacteriol* **187**: 1182-1187.
- 766 Solomon, J.M., B.A. Lazazzera & A.D. Grossman, (1996) Purification and characterization of an  
767 extracellular peptide factor that affects two different developmental pathways in *Bacillus*  
768 *subtilis*. *Genes Dev* **10**: 2014-2024.
- 769 Sonenshein, A.L., (2007) Control of key metabolic intersections in *Bacillus subtilis*. *Nat Rev*  
770 *Microbiol* **5**: 917-927.
- 771 Song, X.M., W. Connor, S. Jalal, K. Hokamp & A.A. Potter, (2008) Microarray analysis of  
772 *Streptococcus pneumoniae* gene expression changes to human lung epithelial cells.  
773 *Can J Microbiol* **54**: 189-200.
- 774 Trombe, M.C., G. Laneelle & A.M. Sicard, (1984) Characterization of a *Streptococcus*  
775 *pneumoniae* mutant with altered electric transmembrane potential. *J Bacteriol* **158**: 1109-  
776 1114.
- 777 Trombe, M.C., M.A. Laneelle & G. Laneelle, (1979) Lipid composition of aminopterin-resistant  
778 and sensitive strains of *Streptococcus pneumoniae*. Effect of aminopterin inhibition.  
779 *Biochim Biophys Acta* **574**: 290-300.
- 780 van Opijnen, T. & A. Camilli, (2012) A fine scale phenotype-genotype virulence map of a  
781 bacterial pathogen. *Genome Res* **22**: 2541-2551.
- 782 Waters, C.M. & B.L. Bassler, (2005) Quorum sensing: cell-to-cell communication in bacteria.  
783 *Annual review of cell and developmental biology* **21**: 319-346.
- 784 Willey, J.M. & W.A. van der Donk, (2007) Lantibiotics: peptides of diverse structure and function.  
785 *Annu Rev Microbiol* **61**: 477-501.
- 786 Yesilkaya, H., S. Manco, A. Kadioglu, V.S. Terra & P.W. Andrew, (2008) The ability to utilize  
787 mucin affects the regulation of virulence gene expression in *Streptococcus pneumoniae*.  
788 *FEMS Microbiol Lett* **278**: 231-235.
- 789 Zahner, D. & R. Hakenbeck, (2000) The *Streptococcus pneumoniae* beta-galactosidase is a  
790 surface protein. *J Bacteriol* **182**: 5919-5921.

791

792

793 **Table 1.** Changes in relative transcript amounts caused by  $\Delta tprA$  and  $\Delta phrA$  mutations or the addition of the 10-residue synthetic  
 794 PhrA peptide<sup>a</sup>

Effect on expression & gene tag	Known or Predicted Function & Gene Name	+PhrA(10) vs. untreated <sup>b</sup>		$\Delta tprA$ vs. WT <sup>c</sup>		$\Delta(tprA-phrA)$ vs. WT <sup>d</sup>		$\Delta phrA$ vs. WT <sup>e</sup>	
		Log <sub>2</sub> fold change	FDR <sup>f</sup>	Log <sub>2</sub> fold change	FDR <sup>f</sup>	Log <sub>2</sub> fold change	FDR <sup>f</sup>	Log <sub>2</sub> fold change	FDR <sup>f</sup>
<b><i>tprA, phrA</i> gene region</b>									
spd1744	lipoprotein, putative	2.7	3.0E-20	3.3	1.5E-27	3.2	5.0E-26		
spd1745	PlcR-family transcription factor, <i>tprA</i>	3.3	4.2E-88						
spd1746	Phr-family peptide signaling precursor protein, <i>phrA</i>	4.7	4.5E-81	5.0	3.7E-103	-4.0	2.4E-19	-4.5	9.1E-22
spd1747	lantibiotic precursor peptide	4.7	1.7E-133	4.7	5.3E-115	5.7	6.7E-217		
spd1748	lantibiotic precursor peptide	4.8	2.6E-80	4.8	2.5E-72	5.7	3.4E-123		
spd1749	bifunctional lantibiotic modification enzyme	3.5	4.3E-37	4.3	4.0E-52	3.9	3.8E-19		
spd1750	FAD-dependent flavoprotein	3.3	4.6E-35	4.2	2.2E-51	3.8	3.4E-24		
spd1751	membrane protein, putative	2.9	8.8E-17	3.8	1.1E-24	3.4	8.7E-14		
spd1752	toxin secretion ABC transporter, ATP-binding/permease protein	3.1	6.3E-18	4.0	1.4E-26	3.6	2.7E-13		
spd1753	serine protease, putative	3.0	4.3E-26	3.8	1.3E-37	3.4	1.3E-13		
spd1754	lantibiotic immunity protein	1.7	2.6E-15	2.4	3.2E-27	2.1	7.7E-11		
spd1755	ABC transporter, ATP-binding protein	1.7	4.4E-16	2.3	6.0E-24	2.0	4.9E-10		
spd1756	unknown	1.6	4.8E-05	2.5	2.7E-12	2.3	1.1E-09		
<b><i>spd0769-0773</i> region</b>									
spd0769	tmRNA, <i>ssrA</i>	2.0	1.5E-06						
spd0771	lactose phosphotransferase system repressor, <i>lacR1</i>	1.5	3.4E-14			1.1	1.4E-05		
spd0772	1-phosphofructokinase	1.6	7.7E-23			1.2	3.7E-12		
spd0773	PTS system fructose specific transporter subunit IIABC	1.5	1.5E-20			1.0	9.5E-06		

**Other Genes**

spd0096	transcriptional regulator, PadR family protein	-1.1	3.4E-04				
spd0104	LysM domain-containing protein					-1.1	3.3E-05
spd0391	conserved hypothetical protein					0.99	2.1E-04
spd0450	type I restriction-modification system subunit S					-1.5	3.1E-06
spd0452	integrase/recombinase, phage integrase family protein					1.3	2.4E-04
spd0460	molecular chaperone, <i>dnaK</i>					-1.2	3.3E-05
spd2013	glycerol kinase, <i>glpK</i>					-1.1	1.8E-04

795 <sup>a</sup> Strain construction, growth and RNA-Seq analysis are described in Experimental procedures. RNA was prepared from  
796 exponential cultures grown in BHI media at 37°C to OD<sub>620</sub> ≈0.15 to 0.2. The Log<sub>2</sub> of the fold changes and FDR values are based on  
797 three independent biological replicates. Cut-offs for this table were 2.0-fold change and FDR value < 0.001. Empty boxes indicate  
798 that there was not a significant change in expression of a gene under one of the four conditions.

799 <sup>b</sup> The RNA transcript levels from strain IU1781 treated with 10 μM 10-residue synthetic PhrA compared to strain IU1781  
800 receiving no treatment. The peptide was added to cells at an OD<sub>620</sub> of 0.03 and then allowed to incubate to the required OD before  
801 harvesting.

802 <sup>c</sup> The RNA transcript levels from  $\Delta tprA$  mutant strain IU4955 were compared to the RNA transcripts from an isogenic strain IU1781.

803 <sup>d</sup> The RNA transcript levels from  $\Delta tprA \Delta phrA$  mutant strain IU6118 were compared to the RNA transcripts from an isogenic strain  
804 IU1781.

805 <sup>e</sup> The RNA transcript levels from  $\Delta phrA$  mutant strain IU4957 were compared to the RNA transcripts from an isogenic strain IU1781.

806 <sup>f</sup> FDR is the false-discovery rate ([Benjamini & Hochberg, 1995](#)).

807 **FIGURE LEGENDS**

808 **Fig 1. TprA serves as an inhibitor of *phrA* expression.**

809 (A) The effect of  $\Delta tprA$  and  $\Delta phrA$  mutations on *phrA-lacZ* expression. Strains: Spn007, “wild-  
810 type” parental strain used in this experiment; Spn013,  $\Delta tprA$ ; Spn019,  $\Delta phrA$ ; Spn195,  $\Delta tprA$   
811 CEP::*TprA* (complemented strain). Results shown are averages of 2-5 independent experiments  
812 and error bars depict the standard error of the mean. \*\*\*, significant at  $P < 0.001$  compared to  
813 “wild type.” +++, significant at  $P < 0.001$  compared to  $\Delta tprA$ . (B) *phrA* mRNA levels in a  $\Delta tprA$   
814 mutant strain. Strains: IU1781 & Spn049, “wild-type” parental strains used in this experiment;  
815 Spn052,  $\Delta tprA$ ; Spn197,  $\Delta tprA$  CEP::*TprA* (complemented strain). mRNA levels were  
816 normalized to 16S RNA levels, from 2 independent experiments, and are shown as a ratio  
817 relative to the wild-type levels. Error bars depict the standard error of the mean. \*, significant at  
818  $P < 0.05$  compared to “wild type.” +, significant at  $P < 0.05$  compared to  $\Delta tprA$ . Different parent  
819 strains were used in these approaches containing wild-type alleles for the genes of interest.

820

821 **Fig 2. Identification of the minimal PhrA-signaling peptide.**

822 (A) *phrA-lacZ* reporter expression is elevated when the full length *phrA* gene is overexpressed.  
823 Strains: Spn065, full length PhrA; Spn191, PhrA $\Delta$ 42-56 ; Spn189, PhrA $\Delta$ 47-56 ; Spn187,  
824 PhrA $\Delta$ 52-56 ; Spn243, PhrA $\Delta$ 56 . Cells were grown in BHI or BHI+1% fucose (inducer) to mid-  
825 exponential phase (OD<sub>620</sub> of between 0.15 to 0.35) when samples were removed for  $\beta$ -  
826 galactosidase activity assays. Results shown are the averages of at least 3 independent  
827 replicates and error bars indicate the standard error of the mean for each set. \*\*\*, significant at  
828  $P < 0.001$  compared to uninduced strain containing the full-length PhrA construct. (B) Synthetic  
829 peptides corresponding to the C-terminus of PhrA used in (C) below. (C) Induction of the *phrA*-  
830 *lacZ* reporter was observed when cells were treated with the last 6, 7, or 10 amino acids of  
831 PhrA. Early exponential phase (OD<sub>620</sub> of ~0.1) wild-type cells (Spn007) were incubated with

832 synthetic peptides at a final concentration of 5  $\mu$ M or peptide-resuspension buffer for two hours  
833 prior to analysis by  $\beta$ -galactosidase assays. Results shown are the averages of at least 3  
834 independent replicates and error bars indicate the standard error of the mean for each set. \*,  
835 significant at  $P < 0.05$  and \*\*, significant at  $P < 0.01$  compared to the “wild type” strain incubated  
836 with buffer.

837

838 **Fig 3. Oligopeptide permease is required for induction of *phrA-lacZ* in response to**  
839 **synthetic peptide.**

840 Strains lacking *amiC* in a wild-type or a  $\Delta tprA$  mutant background were tested for their ability to  
841 induce *phrA-lacZ* expression in response to the 10-residue PhrA peptide. Strains: Spn007, “wild-  
842 type” parental strain used in this experiment; Spn013,  $\Delta tprA$ ; Spn141,  $\Delta amiC$ ; Spn165,  $\Delta tprA$   
843  $\Delta amiC$ . Early exponential phase cells ( $OD_{620}$  of  $\sim 0.1$ ) grown in BHI were incubated with 5  $\mu$ M  
844 synthetic peptide or peptide-resuspension buffer for two hours prior to analysis by  $\beta$ -  
845 galactosidase activity assays. Results shown are the average of at least two independent trials,  
846 and error bars represent the standard error of the mean. \*\*\*, significant at  $P < 0.001$  compared  
847 to the strain treated with buffer.

848

849 **Fig 4. PhrA can signal between cells when grown to high cell density in media containing**  
850 **galactose.**

851 Cells (Spn007, wild-type) grown in CDM-glucose (closed squares) or CDM-galactose (open  
852 circles). Panel A shows a representative growth curve of these cells on these media. Note that  
853 after inoculation of the cultures several hours pass before there is a measurable level of cells,  
854 and this lag phase is longer in CDM-galactose. Panel B shows expression of *phrA-lacZ* in the  
855 Spn007 cells. At least two independent experiments were performed; the results from one  
856 representative experiment are shown. Panel C shows induction of *phrA-lacZ* when these were

857 resuspended in conditioned media from wild-type cells (IU1781) compared to untreated media,  
858 and no induction was observed in conditioned media from cells lacking *phrA* (IU4957). The  
859 results shown are the average of at least two independent trials and the error bars depict the  
860 standard error of the mean. \*, significant at  $P < 0.05$  compared to untreated media. +, significant  
861 at  $P < 0.05$  compared to wild-type conditioned media.

862

863 **Fig 5. The TprA/PhrA system regulates a putative lantibiotic biosynthesis operon.**

864 ORFs are represented by dark grey arrows (in the case of the TprA/PhrA system) or light gray  
865 arrows (for the putative lantibiotic biosynthesis genes) and the D39 gene identification numbers  
866 are indicated in the arrows, with genes *spd1747* and *spd1748* shorten to 47 and 48,  
867 respectively. Known or predicted functions of each gene are indicated above the arrows, and --  
868 indicates that the function of the genes is unknown. The putative promoters, predicted by the  
869 results with RNA-seq, are represented by bent black arrows, and putative promoters predicted  
870 by the DOOR database are shown as bent gray arrows. Small black boxes are predicted CRE-  
871 binding sites of CcpA ([Carvalho et al., 2011](#)). Genes whose expression has been found to be  
872 increased in either a  $\Delta tprA$  mutant or by the addition of the PhrA peptide are denoted by + under  
873 the gene.

874

875 **Fig 6. Model for the mechanism by which PhrA and TprA control gene expression in *S.***

876 ***pneumoniae*.**

877 The mature PhrA peptide is encoded by *phrA* producing a precursor protein in the absence of  
878 glucose. Glucose repression occurs through a CRE element that is in *phrA* promoter region.  
879 The PhrA precursor is exported and processed to release the mature PhrA peptide (dark gray,  
880 small ovals). When at a sufficient concentration, the PhrA peptide interacts with oligopeptide  
881 permease and is transported into the cell where it inhibits the activity of TprA leading to de-  
882 repression of *phrA*, *tprA*, and a change in transcription of lantibiotic genes (wide arrows). Only

883 three of the eight lantibiotic biosynthesis cluster genes are shown here for simplicity (black  
884 outlined, wide arrows with one not shown to scale (angled lines)). Bent arrows indicate the  
885 location of data-supported (black) or predicted (gray) promoters, all of which are negatively  
886 regulated by TprA (denoted by lines that end with a horizontal line).